Martin Fan
Stock Analyst at Wedbush
(3.01)
# 1,462
Out of 5,005 analysts
9
Total ratings
77.78%
Success rate
37.79%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Martin Fan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANAB AnaptysBio | Reiterates: Outperform | $45 | $30.94 | +45.44% | 3 | Sep 30, 2025 | |
| SANA Sana Biotechnology | Initiates: Outperform | $5 | $3.96 | +26.26% | 1 | Sep 24, 2025 | |
| RNAC Cartesian Therapeutics | Initiates: Outperform | $38 | $10.19 | +272.91% | 1 | Jul 9, 2025 | |
| ACRS Aclaris Therapeutics | Initiates: Outperform | $8 | $1.86 | +330.11% | 1 | May 28, 2025 | |
| ORKA Oruka Therapeutics | Reiterates: Outperform | $40 | $19.79 | +102.12% | 1 | May 15, 2025 | |
| ARTV Artiva Biotherapeutics | Reiterates: Outperform | $18 | $2.95 | +510.17% | 1 | Mar 25, 2025 | |
| ZBIO Zenas BioPharma | Initiates: Outperform | $35 | $21.76 | +60.85% | 1 | Mar 20, 2025 |
AnaptysBio
Sep 30, 2025
Reiterates: Outperform
Price Target: $45
Current: $30.94
Upside: +45.44%
Sana Biotechnology
Sep 24, 2025
Initiates: Outperform
Price Target: $5
Current: $3.96
Upside: +26.26%
Cartesian Therapeutics
Jul 9, 2025
Initiates: Outperform
Price Target: $38
Current: $10.19
Upside: +272.91%
Aclaris Therapeutics
May 28, 2025
Initiates: Outperform
Price Target: $8
Current: $1.86
Upside: +330.11%
Oruka Therapeutics
May 15, 2025
Reiterates: Outperform
Price Target: $40
Current: $19.79
Upside: +102.12%
Artiva Biotherapeutics
Mar 25, 2025
Reiterates: Outperform
Price Target: $18
Current: $2.95
Upside: +510.17%
Zenas BioPharma
Mar 20, 2025
Initiates: Outperform
Price Target: $35
Current: $21.76
Upside: +60.85%